---
title: 'Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week
  analysis of the Phase 1/2 Alta study'
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37871576/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231024180819&v=2.17.9.post6+86293ac
source: Blood
description: Patients with hemophilia A require exogenous factor VIII (FVIII) or non-factor
  hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus
  (AAV) vector-based gene therapy is under clinical investigation to enable endogenous
  FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector
  containing the coding sequence for the B-domain-deleted human F8 gene. In the ongoing
  phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants ...
disable_comments: true
---
Patients with hemophilia A require exogenous factor VIII (FVIII) or non-factor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector-based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain-deleted human F8 gene. In the ongoing phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants ...